title: Re: Wolfe et al. Do rheumatology cost-effectiveness analyses make sense?
authors.forename: A
authors.initials: A
authors.lastname: Brennan
authors.forename: N
authors.initials: N
authors.lastname: Bansback
mesh_terms: D018501:Antirheumatic Agents / Q000191:economics*; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D006801:Humans; D017059:Models, Econometric; D012216:Rheumatic Diseases / Q000191:economics*
chemical_list: D018501:Antirheumatic Agents